Ministry of Trade, Industry and Energy's 'SME Symbiosis Innovation Project' national project
Blood analyzer applying AI deep learning technology, jointly developed with the National Cancer Center
Synopex announced that it has successfully completed the Ministry of Trade, Industry and Energy's 'SME Symbiosis Innovation Project' national project (Project Name: Development of a Peripheral Blood-Based General Blood Diagnosis and Blood Cancer Cell Analysis System based on Edge Computing).
Synopex announced that it presented the development results at the final evaluation committee of the SME Symbiosis Innovation Project and received notification from the Korea Institute for Advancement of Technology that the national project had been completed.
This national project was carried out as a project of the Ministry of Trade, Industry and Energy's 'SME Symbiosis Innovation Project' in 2022, with Synopex as the principal company and the National Cancer Center and Health Connect as joint research and development organizations.
Through this project, Synopex developed a △blood cell analyzer (model name Lumiio) and a △cartridge applying Lab on a Chip technology. The blood cell analyzer was registered as a Class 1 in vitro diagnostic device for the automatic blood cell counter item by the Ministry of Food and Drug Safety in January of this year (Product Approval Number: In Vitro Diagno 24-92).
In particular, Synopex announced that it has also filed for patents on 6 new technologies applied to this blood analysis system.
The blood cell analyzer (Lumiio) developed by Synopex is a miniature product measuring approximately 15 centimeters in width, length, and height and weighing 1.23 kg. It is a professional product that can be used in hospitals.
The Lumiio developed by Synopex uses its own refractive optical technology and features AI integration.
The AI-equipped Lumiio can monitor diseases such as inflammatory diseases, thrombocytopenia, anemia, and infections through morphological analysis of blood cells based on data learned through deep learning. It can also provide basic data for diagnosing blood cancers such as leukemia and lymphoma through abnormal blood cell analysis.
In addition, the cartridge applying Lab on a Chip technology is an innovative product that can perform the four steps of blood smear, drying, staining, and washing required for general manual blood analysis through a disposable cartridge.
In particular, Synopex announced that it has successfully developed a vibration-type micro pump that dramatically reduces the cost by replacing the expensive micro pump required for the cartridge, making it possible to use a disposable cartridge.
Dr. Min-Chul Hong of Synopex's Artificial Kidney R&D Center said, "Based on the success of this national project, we plan to further upgrade the cartridge applying Lab on a Chip technology by the end of this year to secure mass production capability and enhance its completeness. We also plan to increase the types of diseases that can be analyzed with blood and improve accuracy. We aim to contribute to the promotion of national health and cost reduction in medical care through an innovative system that enables blood diagnosis and morphological analysis of blood in just 10 minutes with a single drop of blood (30 μL), as well as the ability to transmit data to mobile phones and print outputs. This will lead to early diagnosis of severe diseases."
Synopex aims to strengthen its medical device business competitiveness and grow into a global company through synergy between its ongoing hemodialysis business and its blood diagnostic business, which enables health management and early diagnosis of severe diseases.
Website: http://www.synopex.com
Contact
Synopex
IR Team
Pro Choi Won-chul
031-379-7777
Comments0